Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia
The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safet...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wolters Kluwer Medknow Publications
2023-10-01
|
| Schriftenreihe: | Hematology/Oncology and Stem Cell Therapy |
| Schlagworte: | |
| Online-Zugang: | https://journals.lww.com/10.56875/2589-0646.1039 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|